Veracyte is a pioneering genomic diagnostics company. Their tests are dramatically improving clinical outcomes for patients by resolving inconclusive results from traditional diagnostic methods. 

Biotechnology

Veracyte

Annie McGuire joined Veracyte in February 2022 as Senior Vice President and General Counsel, overseeing all aspects of the company’s legal functions. In her role, Ms. McGuire leverages more than 15 years of experience in Fortune 100 and other healthcare companies. Prior to joining Veracyte, Ms. McGuire served as General Counsel and Corporate Secretary at Rakuten Medical, Inc., a global biotechnology company. Prior to that, Ms. McGuire was Vice President, Legal at MyoKardia, Inc., a biotechnology company focused on serious cardiovascular disease, where she helped lead the team through MyoKardia's $13 billion acquisition by Bristol Myers Squibb. Before that, she spent 13 years at Amgen, Inc. where she held various legal and compliance leadership roles, including Senior Corporate Counsel for global commercial operations and employment and executive compensation. Ms. McGuire began her legal career at Proskauer Rose LLP in New York City. She earned her Juris Doctor from New York Law School, Magna Cum Laude, and her Bachelor of Science degree from Pace University, Summa Cum Laude.

Annie McGuire

Rebecca Chambers has extensive healthcare leadership experience, previously serving as Chief Financial Officer for Outset Medical, a publicly traded medical technology company focused on reducing dialysis costs and complexity. While at Outset Medical, Ms. Chambers led the company through a new debt arrangement, Series E fundraising, IPO, and multiple follow-on offerings. Prior to joining Outset, Ms. Chambers served in several financial roles at Illumina, including Vice President of Financial Planning and Analysis, Vice President of Investor Relations and Treasury, and Senior Director of Investor Relations. She has also served as head of Investor Relations and Corporate Communications at Myriad Genetics and held various roles in investor relations at Life Technologies. Earlier in her career, Ms. Chambers served as a Vice President at Bank of America and a Senior Research Associate at Millennium Pharmaceuticals (now part of Takeda Pharmaceuticals). Ms. Chambers serves on the board of Inari Medical, a medical device company focused on venous diseases. She holds a B.S. in Biology from John Carroll University and an M.B.A. from The S.C. Johnson Graduate School of Management at Cornell University.

Rebecca Chambers

Jens Holstein is the current Director at [Veracyte](/org/veracyte). Prior to this, they served as the Chief Financial Officer for MorphoSys AG, [Fresenius Kabi](/org/fresenius-kabi) Asia Pacific, and [Fresenius Kabi](/org/fresenius-kabi) Europe & Middle East. Jens also has experience as a Commercial Director and Non Executive Board Member. Jens has been working in the Biotech industry for over 20 years and is considered a leader in the development of antibodies as therapeutic drugs.

Jens Holstein has a diploma in business administration from the Westfälische Wilhelms-Universität Münster and has also completed a General Leadership Seminar at [Harvard Business School](/org/harvard-business-school). Prior to their current role, they worked as an Industriekaufmann at Bayer AG.

Jens Holstein

Jonathan Wygant joined Veracyte in February 2022 as Vice President and Chief Accounting Officer, overseeing all aspects of the company’s global accounting operations, financial reporting and tax functions. Mr. Wygant has nearly 20 years of experience leading accounting operations for various healthcare and biotechnology companies. Prior to joining Veracyte, he served as Corporate Controller at Biosplice Therapeutics, Inc., a clinical-stage biotechnology company, where he led all finance, accounting and reporting functions. Prior to that, Mr. Wygant was the Chief Financial Officer at Cibus Global, LLC., an agricultural biotechnology company. He also served as Vice President, Controller and Chief Accounting Officer at Alere, Inc., a $2.5B point-of-care diagnostics company which was acquired by Abbott. Prior to that, Mr. Wygant served as Senior Vice President, Controller and Chief Accounting Officer at CareFusion, a $3.5B global medical technology and manufacturing company that was acquired by BD (Becton, Dickinson and Company). Mr. Wygant began his career in accounting with PricewaterhouseCoopers and holds a Bachelor of Accountancy from the University of San Diego.

Jonathan Wygant

Eliav Barr, M.D., joined the Veracyte board of directors in August 2022. Dr. Barr built his distinguished career at Merck Research Laboratories (MRL), a division of Merck & Co., Inc., a multinational pharmaceutical company, where he has served as Head of Global Clinical Development and Chief Medical Officer since April 2022. In this role, he oversees development programs for pipeline and in-line products in the Cardiovascular, Diabetes/Endocrine/ Metabolism, Immunology, Neurology, Oncology, Psychiatry, Respiratory, and Vaccines/Infectious Diseases therapeutic areas. He is also the Chairperson of the Late Development Review Committee at MRL, the governance committee that oversees such pipelines. Dr. Barr has held numerous leadership positions within MRL since joining the company in 1995, including serving as Senior Vice President, Global Medical and Scientific Affairs from 2018 to 2022. He previously served as Senior Vice President, Infectious Diseases and Vaccines from 2016 to 2018. Notably, he led the development of Merck’s human papillomavirus (HPV) vaccines, which have become key tools in the global effort to reduce the burden of certain cancers and diseases caused by HPV. Prior to joining Merck, Dr. Barr pursued post-doctoral training at the University of Michigan and was on faculty at the University of Chicago. He holds a B.S. from Pennsylvania State University and an M.D. from Jefferson Medical College of Thomas Jefferson University and completed an Internal Medicine residency and Cardiology Fellowship at Johns Hopkins.

Eliav Barr

Fabienne Hermitte, Ph.D., brings deep expertise in clinical diagnostics to her role at Veracyte. She cofounded HalioDx, an immuno-oncology diagnostics company, in 2015. At HalioDx, she led the Regulatory, Quality, Medical Affairs, Clinical Development and Diagnostic Marketing teams prior to the company’s acquisition by Veracyte in August 2021.

Prior to HalioDx, Dr. Hermitte, a molecular biologist, cofounded Ipsogen in 1999, where she led the development and international registrations of more than 80 molecular diagnostic products for the diagnosis and disease monitoring of leukemias. When Ipsogen was acquired by Qiagen in 2011, she joined the Qiagen Development & Regulatory leadership teams and oversaw the clinical validation and FDA submission of the Ipsogen JAK2V617F molecular diagnostic kit.

Dr. Hermitte holds a Ph.D. in molecular biology and two Masters degrees in Life Science and Health from AgroParisTech and Paris Sud School of Medicine.

Fabienne Hermitte

Steven French joined Veracyte in July 2022. Mr. French brings more than 20 years of information and operational leadership experience in the life sciences and technology industries. He most recently served as President of a consultancy advising leading biotech companies on information technology strategy, cybersecurity, acquisitions and infrastructure integration, and business operations. Mr. French previously served as Chief Information Officer at Celularity, a clinical-stage biotechnology company. Prior to that, Mr. French was Vice President of Technology Development at Human Longevity, Inc., a San Diego-based venture focused on building a comprehensive database of human genotypes and phenotypes, where he developed and implemented the infrastructure for key data management strategies. Earlier, Mr. French was Co-Founder and Vice President of Strategy and Technology at Epic Sciences, a diagnostics company focused on advancing the treatment and management of cancer, where he established key strategies for information technology, software development, and quality systems. Mr. French holds a B.B.A. and an M.B.A from the University of San Diego.

Steven French

Tina S. Nova, Ph.D., serves as President of Veracyte’s CLIA U.S. Business. In this role, she leads all aspects – market development, product marketing, reimbursement, sales and lab operations – of the company’s broad menu of diagnostic tests that are performed in its laboratories, serving physicians and their patients in the United States.  Dr. Nova is a life science industry veteran with extensive experience building and leading novel genomics-based businesses. She most recently served as Veracyte’s General Manager of Thyroid and Urologic Cancers, and previously served as Chief Executive Officer of Decipher Biosciences prior to Veracyte’s March 2021 acquisition of the company. Prior to that, she was President and Chief Executive Officer of Molecular Stethoscope, Inc., a molecular diagnostics company, and before that served as Senior Vice President and General Manager of Illumina’s oncology business unit. From 2000 to 2014, Dr. Nova was a Co-founder and Director, President and Chief Executive Officer of Genoptix Medical Laboratory, which was purchased by Novartis Pharmaceuticals Corporation. She has also held senior positions with Nanogen, Inc., Ligand Pharmaceuticals, Inc. and Hybritech, Inc. Dr. Nova currently serves on the board of directors for Arena Pharmaceuticals and Exagen, and previously served on Veracyte’s board of directors. She holds a B.S. degree in Biological Sciences from the University of California, Irvine, and a Ph.D. in Biochemistry from the University of California, Riverside.

Tina S. Nova

Corinne Danan serves as Veracyte’s General Manager, Biopharma, leading the company’s offerings to biopharmaceutical companies. Ms. Danan brings more than 30 years of executive experience in the pharmaceutical, life sciences and healthcare industries, as well as strong leadership in Commercial Operations, to her role at Veracyte.

She cofounded and was a member of the board of HalioDx, an immuno-oncology diagnostics company acquired by Veracyte in August 2021. At HalioDx, Ms. Danan led the creation and development of the Pharma business unit, bringing to the company’s biopharmaceutical partners various solutions to support better understanding of the tumor microenvironment within different phases of clinical trials.

Prior to HalioDx, Ms. Danan held senior positions at leading diagnostics companies, including Qiagen, where she was Head of Market Development and Management in EMEA; Ipsogen, where she served as Vice President of Commercial Operations; and Monogram Biosciences, where she was the EU General Manager. Earlier in her career, she held various leadership positions at Eli Lilly.

Ms. Danan holds an MBA from INSEAD Business School.

Corinne Danan

Stephane Debono is Executive Vice President and General Manager, In Vitro Diagnostics (IVD) and EMEA Organizations for Veracyte, overseeing development, manufacturing, market access, sales and marketing of the company’s IVD tests, which serve physicians and their patients in global markets. Mr. Debono is a seasoned executive and entrepreneur who brings more than 25 years of life sciences and healthcare experience to Veracyte. He most recently served as the company’s General Manager of Immunoscore and International Diagnostics Operations. He previously served as Deputy Chief Executive Officer of HalioDx prior to its acquisition by Veracyte in August 2021. Mr. Debono co-founded Ipsogen in 1999 and successfully developed and managed the company’s operations, including services and product manufacturing, as well as its finances and shareholder reporting. Following Ipsogen’s acquisition by Qiagen in 2011, Mr. Debono oversaw European molecular diagnostics manufacturing operations for Qiagen’s IVD products in cancer and infectious diseases. Mr. Debono holds an Engineering degree from École Centrale de Marseille and a Master’s degree in Finance from Euromed Marseille.

Stephane Debono

Rob Brainin is a seasoned professional with over 20 years of executive life sciences and healthcare experience, and a proven track record of using emerging technologies and data science to improve healthcare. Prior to joining Veracyte, Mr. Brainin served as Chief Executive Officer at Genuity Science, a company focused on integrating clinical and molecular data to derive insights that accelerate drug discovery and development. He also previously served as the Vice President and General Manager of the Life Sciences and Applied Genomics Business at Illumina, and as Vice President and General Manager of the Enterprise Genomics Solutions business of Thermo Fisher Scientific, Inc. From 2004 to 2014, Mr. Brainin served in several positions at Life Technologies and its predecessor Invitrogen, predominantly leading a variety of large businesses that served customers in the academic, clinical and biopharma segments. Earlier in his career, Mr. Brainin was a Management Consultant at McKinsey & Co., and has served as an Adjunct Professor at the University of San Diego School of Law. He is a member of the Board of Directors for Champions Oncology and the Children’s Tumor Foundation. Mr. Brainin holds a B.A. in Economics from Emory University and received his Juris Doctor degree from Harvard Law School.

Rob Brainin

Bonnie H. Anderson is Co-founder and Executive Chairwoman of Veracyte, a global diagnostics company that aims to transform outcomes for patients all over the world at every step of their journey in cancer and other diseases. Ms. Anderson’s career spans over 40 years in regulated diagnostics and life science markets. She co-founded Veracyte in 2008 and served as Chief Executive Officer and Chairman of the Board until June 1, 2021, when she assumed the role of Executive Chairwoman. Ms. Anderson led Veracyte’s initial public offering in 2013, spearheaded commercialization of its market-leading products; and was the architect of the company’s vision to become a global enterprise with a growing menu of advanced genomic diagnostics tests and its own distributed instrument platform.

Prior to Veracyte, Ms. Anderson provided strategic consulting services to venture capital firms and early-stage businesses following 18 years in leadership positions at Beckman Coulter. She serves on the boards of Bruker Corporation, DNA Script and the Biotechnology Innovation Organization (BIO), and is a trustee emeritus of the Keck Graduate Institute of Applied Life Sciences. Additionally, Ms. Anderson is President of the Coalition for 21st Century Medicine and previously served on the board of Castle Biosciences. She has received numerous awards for her industry leadership, including: the Wallace H. Coulter Award for Healthcare Innovation (2017); “Fiercest Women in Life Sciences” (FiercePharma, 2017); “100 Most Creative People in Business” (Fast Company, 2015); “Most Influential Women in Bay Area Business” and “Bay Area’s Most Admired CEOs” (San Francisco Business Times, 2013 and 2014); and “Women of Influence” (Silicon Valley Business Journal, 2013). Under Ms. Anderson’s leadership, Veracyte has been named a “Top Workplace” by the Bay Area News Group, based solely on employee feedback, for seven consecutive years (2014-2020). Ms. Anderson graduated from Indiana University of Pennsylvania with a B.S. in Medical Technology and in 2012 was honored with a “Distinguished Alumni” award.

Bonnie H. Anderson

Tracy Morris joined [Veracyte](/org/veracyte) in April 2020 as Vice President, Corporate Communications and Investor Relations. In this role, she works in tandem with the Chief Executive Officer and executive team to communicate the company’s strategic vision and value proposition to investors and other audiences and ensures that the market-leading company’s brand is articulated in product and other communications. Ms. Morris has over 25 years of experience in healthcare communications and public relations. Prior to joining [Veracyte](/org/veracyte), she served as a strategic communications consultant to the company for nearly 10 years, as well as to other diagnostics innovators, ranging from start-ups to Fortune 500 companies. Earlier in her career, Ms. Morris was Director of U.S. Marketing Communications for Digene Corporation, a molecular diagnostics company that pioneered HPV testing in cervical cancer early detection. She previously served as Senior Vice President of Healy Communications, a Chicago-based public relations firm (acquired by [Finn Partners](/org/finn-partners)), and began her career at Edelman Public Relations in Washington, DC. Ms. Morris holds a B.A. in English from the College of William and Mary in Williamsburg, Virginia.

Tracy Morris

Morten Frost joined [Veracyte](/org/veracyte) in January 2021 as General Manager, Pulmonology, with global responsibility for strategic business planning and tactical execution, for the company’s lung cancer and interstitial lung disease (ILD) products. Mr. Frost will lead the planned 2021 launches of the company’s noninvasive nasal swab test for early lung cancer detection, its Percepta Genomic Atlas lung cancer genomic profiling test and its global introduction of the Envisia classifier for improved ILD diagnosis on the nCounter system. Mr. Frost comes to [Veracyte](/org/veracyte) with significant strategic consulting, sales and marketing experience. He was most recently at [Agilent Technologies](/org/agilent-technologies), where he served as Associate Vice President, Head of Global Marketing for the company’s pathology and companion diagnostics business. In this role, he drove significant revenue growth, global product launches, biopharmaceutical partnerships and M&A strategy. Prior to that, Mr. Frost served as a management consultant at IMS Consulting Group (Now [IQVIA](/org/iqvia)) where he advised leading pharmaceutical companies on top-line growth and commercial strategy. He holds an MSc in Economics and Business Administration from [Copenhagen Business School](/org/copenhagen-business-school) in Denmark with complementary executive MBA courses from [Stanford University](/org/stanford).

Morten Frost

Marc Stapley became Chief Executive Officer of Veracyte on June 1, 2021, and also serves on the company’s board of directors.

Mr. Stapley has deep experience in the genomic diagnostics industry, including significant expertise in building and leading complex global operations. Prior to joining Veracyte, he was Chairman and CEO of Helix, a leading population genomics company, from April 2019 to May 2021. Under Mr. Stapley’s leadership, Helix built one of the largest COVID-19 testing labs in the United States and became a national leader in viral surveillance.

Prior to Helix, Mr. Stapley served in key executive leadership positions at Illumina, the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. While at Illumina, he served as Chief Financial Officer, Chief Administrative Officer, and Executive Vice President over the course of seven years, where he led many functions including G&A, corporate strategy, business development, population genomics and government affairs.

Before joining Illumina, Mr. Stapley was Senior Vice President, of Finance at Pfizer Inc. and was responsible for global financial processes and systems, leading integration efforts for key acquisitions and providing oversight to the company’s largest technology investment program. Prior to that, he served in a variety of senior finance roles at Alcatel-Lucent, Cadence Design Systems, Inc., and Coopers & Lybrand (now PwC).

Mr. Stapley holds a B.Sc. (Honors) in Mathematics from The University of Reading (England) and is a member of the Institute of Chartered Accountants in England and Wales. He is a member of the board of directors of Helix, Glaukos (GKOS), and Premier Food Concepts.

Marc Stapley

Karin Eastham has spent their career in the healthcare industry, working with leading companies to improve patient care. Karin is currently the Director at [Veracyte](/org/veracyte), a position they have held since December 2015. Prior to joining [Veracyte](/org/veracyte), Karin served on the Board of Directors for [Nektar Therapeutics](/org/nektar-therapeutics), [AltheaDx](/org/altheadx), and MorphoSys AG. Karin also served as Co-Chair of Women Corporate Directors from 2013 to 2014. Karin has a deep commitment to improving healthcare and has been recognized for their work in this area. In 2019, they were named one of the 100 Most Influential People in Healthcare by [Modern Healthcare](/org/modern-healthcare).

Karin Eastham has an MBA in Finance from the Indiana University - Kelley School of Business and a B.S. in Accounting from the same school.

Karin Eastham

Evan Jones

Robert S. Epstein

Muna Bhanji

Edison Liu is the President and CEO of the Jackson Laboratory, bringing his passion for personalized medicine to leading the development and utilization of complex mouse models for basic and translational research. Previously, he was the founding Executive Director of the Genome Institute of Singapore and served in similar capacities at the Singapore Cancer Syndicate and Singapore Tissue Network. Dr. Liu has won numerous awards for his work, most recently earning honors as Associate Member of the European Molecular Biology Organization (EMBO), Public Service Medal for controlling SARS in Singapore and an election to the board of directors at the American Association for Cancer Research. He is the President of the Human Genome Organisation (HUGO) and previously Chairman of the Health Sciences Authority in Singapore, among numerous other committees and advisory boards. Dr. Liu has authored more than 200 publications detailing his work on the involvement of kinases in cancer biology and molecular clinical epidemiology and functional genomics of human cancers. Dr. Liu earned his M.D. from [Stanford University](/org/stanford) and was a resident at Barnes Hospital at Washington University, St. Louis.

Edison Liu

Mr. Bishop began serving as a member of our board of directors in December 2014, and was subsequently appointed Lead Independent Director in December 2016. Mr. Bishop retired at the end of 2016 as Chairman and Chief Executive Officer of [Cepheid](/org/cepheid), a leading global molecular diagnostics company, following the acquisition of [Cepheid](/org/cepheid) by [Danaher](/org/danaher) in November of 2016. Prior to that, he was President and Chief Executive Officer of Vysis, Inc., a genomic disease management company that was acquired by Abbott Laboratories. From 1991 until 1993, Mr. Bishop was Chairman and Chief Executive Officer of MicroProbe Corporation, a biotechnology company, and from 1987 until 1991, of Source Scientific Systems Inc., a biomedical instrument manufacturing company. Prior to that, from 1984 to 1986, he was President and Chief Operating Officer of Gen-Probe, Inc., a molecular diagnostics company.  Mr. Bishop served as a director of Conceptus, Inc., a medical device company, from February 2009 until June 2013 when it was acquired by Bayer HealthCare LLC. He also served as a member of the AdvaMedDx Board, a medical diagnostics industry advocacy group, since 2010 — serving as Chairman from December 2013 to April 2017. 

Veracyte

Org chart

Teams

Board of Directors

Leadership Team

CEO and Executive Team

Discover similar companies